Advertisement
UK markets closed
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • FTSE 250

    19,179.56
    -83.94 (-0.44%)
     
  • AIM

    747.77
    -2.19 (-0.29%)
     
  • GBP/EUR

    1.1704
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2672
    +0.0014 (+0.11%)
     
  • Bitcoin GBP

    40,667.53
    +37.07 (+0.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • DOW

    39,131.53
    +62.43 (+0.16%)
     
  • CRUDE OIL

    76.57
    -2.04 (-2.60%)
     
  • GOLD FUTURES

    2,045.80
    +15.10 (+0.74%)
     
  • NIKKEI 225

    39,098.68
    +836.48 (+2.19%)
     
  • HANG SENG

    16,725.86
    -17.04 (-0.10%)
     
  • DAX

    17,419.33
    +48.93 (+0.28%)
     
  • CAC 40

    7,966.68
    +55.08 (+0.70%)
     

BUZZ-GlaxoSmithKline Plc: Shingles vaccine could be better than Merck's - Cowen

** Drugmaker's U.S.-listed shares up 1.3 pct at $46.75 premarket, London-listed up nearly 2 pct

** Cowen & Co analysts say GSK's vaccine to treat shingles may be more effective than Merck (LSE: 0O14.L - news) 's

** Glaxo's vaccine HZ/su should be well positioned to capture market share from Merck's Zostavax if final data from a late-stage study shows HZ/su has better efficacy while treating older patients, Cowen says

** Final data from late-stage study expected in H1 2015

** Merck sold $765 mln worth Zostavax worldwide in 2014

** Barclays (LSE: BARC.L - news) raised its price target on European drugmakers, including GSK's London-listed stock

** GSK up nearly 2 pct on the LSE

** Through Monday, the U.S. stock had gained 10 pct since Dec. 18, when GSK reported early data from the late-stage study